Corticosteroids in allergy and airway disease: treat the inflammatory process, but always plan safety, route and stopping
Corticosteroids are not simply “strong anti-allergy tablets.” They are adrenal hormones and synthetic analogues with major glucocorticoid and/or mineralocorticoid actions. In allergy, asthma, rhinitis, eczema and immune disease they suppress many inflammatory pathways more broadly than antihistamines. This can protect life and organs, but can also cause infection, diabetes, hypertension, osteoporosis, psychiatric disturbance, cataract/glaucoma and adrenal suppression. The safest treatment is the least systemic exposure that achieves the clinical objective: correct diagnosis, local route where possible, a defined duration, monitoring and an exit plan.
Emergency allergy: steroid is an adjunct, not first-line lifesaving treatment
In suspected anaphylaxis—airway compromise, breathing difficulty, shock or rapidly progressive multisystem reaction—give intramuscular adrenaline and emergency ABC management according to protocol. Corticosteroids have delayed genomic effects and must never delay adrenaline, oxygen, fluids, bronchodilator or urgent transfer.
What this post adds to the SAIDs foundation
The earlier SAIDs lesson explains general glucocorticoid pharmacology. This companion post exhausts the supplied 65-slide corticosteroid lecture through the clinical anti-allergic lens: adrenal physiology, potency/route selection, inhaled/nasal/topical/systemic use, asthma and allergic emergencies, infection precautions, steroid stewardship, tapering and patient counselling. It therefore supports students in choosing and monitoring treatment rather than memorising a long list of indications.
1. Adrenal cortex, biosynthesis and regulation
The adrenal cortex forms steroid hormones from cholesterol. The zona glomerulosa produces mineralocorticoids (mainly aldosterone), the zona fasciculata produces glucocorticoids (mainly cortisol), and the zona reticularis produces adrenal androgens. ACTH is particularly important for cortisol synthesis; aldosterone is governed mainly by the renin–angiotensin–aldosterone system and plasma potassium.
| Axis or hormone | Normal role | Why it matters clinically |
|---|---|---|
| CRH → ACTH → cortisol (HPA axis) | Hypothalamic CRH stimulates pituitary ACTH; ACTH stimulates adrenal cortisol. Cortisol gives negative feedback. | Exogenous systemic steroid suppresses CRH/ACTH. Abrupt cessation after significant exposure can leave inadequate endogenous cortisol. |
| Circadian rhythm | Cortisol is highest in early morning and lowest around midnight. | When compatible with disease control, a single morning glucocorticoid dose better follows physiology and may reduce HPA suppression. |
| Cortisol in stress | Illness, trauma, surgery and severe inflammation require higher cortisol output. | Patients dependent on replacement or at risk of adrenal suppression may need protocolled stress-dose cover; this is not optional “extra medicine.” |
| Aldosterone | Promotes distal sodium retention and potassium/hydrogen excretion. | Mineralocorticoid activity explains oedema, hypertension, hypokalaemic alkalosis and heart-failure worsening with some steroids. |
2. Physiological actions explain the adverse effects
| Glucocorticoid action | Adaptive purpose | Pharmacological excess |
|---|---|---|
| Increased hepatic gluconeogenesis and reduced peripheral glucose utilisation | Provides fuel during stress. | Hyperglycaemia, insulin resistance and steroid-induced diabetes. |
| Protein catabolism and amino-acid mobilisation | Supplies substrate for hepatic synthesis. | Proximal muscle weakness, wasting, thin skin, bruising, poor healing, negative nitrogen balance and bone loss. |
| Fat mobilisation plus redistribution | Energy availability. | Truncal obesity, moon facies, dorsocervical fat pad and dyslipidaemia. |
| Reduced gut calcium absorption/increased renal loss and reduced bone formation | Not a desired treatment effect. | Osteoporosis, fragility fractures, growth impairment and delayed repair. |
| Maintains vascular response to catecholamines and GFR/water excretion | Supports circulation during stress. | Loss in adrenal insufficiency contributes to hypotension/collapse; excessive mineralocorticoid effect promotes fluid retention and BP rise. |
| Suppresses immune-cell recruitment, cytokines and eicosanoids | Limits excessive tissue injury. | Infection susceptibility, muted inflammatory signs and reactivation of latent infection. |
3. Anti-inflammatory and anti-allergic mechanism: why corticosteroids are broader than antihistamines
Glucocorticoids enter cells and bind intracellular glucocorticoid receptors. The complex moves to the nucleus, changing gene expression. They increase anti-inflammatory proteins (including annexin A1/lipocortin) and repress NF-κB/AP-1-regulated inflammatory genes. This decreases phospholipase A2-driven arachidonic acid release, COX-2 expression, cytokines, adhesion molecules, chemotaxis, leucocyte migration, lysosomal enzymes, vascular permeability and mediator generation.
| Inflammatory target | Corticosteroid effect | Clinical outcome and limitation |
|---|---|---|
| Eosinophils, T cells, macrophages and antigen presentation | Reduced activation, survival, migration and cytokine production; lymphocyte redistribution/lympholysis. | Controls allergic/autoimmune inflammation but impairs host defence. |
| Prostaglandins, leukotrienes, PAF and cytokines | Reduced production through upstream and transcriptional effects. | More comprehensive anti-inflammatory effect than H1 antihistamine; delayed onset means it cannot substitute for adrenaline in anaphylaxis. |
| Capillaries/lysosomes | Reduced permeability/exudation and reduced lysosomal enzyme release. | Less oedema and tissue damage; also delayed healing and masked infection. |
| Fibroblasts/collagen repair | Suppressed proliferation and repair. | May reduce scarring in selected use, but causes thin skin/striae/poor wound healing and silent perforation risk in severe disease. |
4. Individual corticosteroids: select by potency, duration and mineralocorticoid activity
| Drug | Practical profile | Typical roles from the supplied lecture | Key caution |
|---|---|---|---|
| Hydrocortisone | Short acting; meaningful glucocorticoid and mineralocorticoid activity. | Adrenal replacement/crisis protocols; selected acute severe inflammatory/allergic care, status asthmaticus pathways, topical or rectal formulations. | Fluid/salt retention at pharmacological exposure; follow exact emergency/replacement protocol. |
| Prednisone / prednisolone | Intermediate acting, more glucocorticoid-selective than hydrocortisone; oral workhorse in many settings. | Allergic and inflammatory conditions, autoimmune disease, malignancy and short oral courses for indicated asthma exacerbation. | Prednisone requires hepatic activation; do not create repeated open-ended courses without review. |
| Methylprednisolone | Intermediate acting with low mineralocorticoid action; oral/IV preparations. | Selected severe inflammatory disease, pulse regimens, transplant/renal/pemphigus and some IBD preparations. | “Pulse” is a specialist/protocolled strategy, not simply a very high dose for ordinary symptoms. |
| Triamcinolone | Potent glucocorticoid used in topical, local and some intra-articular formulations. | Selected inflammatory skin/joint applications. | Exclude joint/skin infection; injection can still cause systemic glucose/HPA effects. |
| Dexamethasone | Potent, long acting and minimal mineralocorticoid action. | Selected cerebral oedema, antiemetic, severe inflammatory/allergic and endocrine-test protocols. | Long biological action means substantial HPA suppression risk; do not interchange casually with hydrocortisone. |
| Betamethasone | Potent long acting glucocorticoid. | Specialist obstetric and inflammatory/dermatologic protocols. | Route, timing and formulation matter; do not use as a generic “strong steroid.” |
| Fludrocortisone | Predominantly mineralocorticoid with some glucocorticoid action. | Primary adrenal failure and selected congenital-adrenal-hyperplasia replacement protocols. | Not an anti-allergy corticosteroid; monitor BP, oedema and potassium. |
5. Route is a safety decision: localise treatment whenever possible
| Route | Clinical use | Technique/safety essentials |
|---|---|---|
| Inhaled | Controller therapy for asthma; selected COPD regimens. | Not a rescue bronchodilator. Check inhaler technique/adherence, rinse mouth or use spacer where appropriate to reduce thrush/dysphonia, and consider systemic effects at high dose or with CYP3A4 inhibitors. |
| Intranasal | Allergic rhinitis, nasal polyps and persistent nasal inflammation. | Often more effective for nasal obstruction than oral antihistamine. Teach spray away from septum; epistaxis, irritation and poor technique are common reasons for failure. |
| Topical skin | Eczema/dermatitis and selected inflammatory dermatoses. | Match potency to body site, severity, age and diagnosis; face/flexures/thin skin need special caution. Do not treat undiagnosed fungal/scabies/bacterial disease with escalating steroid. |
| Ophthalmic | Selected allergic/inflammatory eye disease. | Painful red eye, photophobia, visual loss or suspected herpes/infection requires examination. Steroids can raise IOP and worsen untreated infection. |
| Oral | When systemic inflammation is significant or local treatment is inadequate. | Define indication, dose, duration, review date, monitoring and taper plan before first tablet. |
| IV/IM | Severe acute disease, inability to take oral medicine or emergency/specialist protocol. | Switch to the least intensive route promptly when safe; IV route does not make adverse effects disappear. |
| Intra-articular/rectal/local | Selected joint, IBD and local inflammatory conditions. | Screen for infection and systemic risk; document site/product/response and avoid repetitive blind injections. |
6. Corticosteroids in anti-allergic disease and asthma
| Condition | Role | Do not miss |
|---|---|---|
| Allergic rhinitis | Intranasal corticosteroid is highly effective, particularly for congestion; may be combined with non-sedating oral/intranasal antihistamine. | Technique, regular use during exposure period, saline/allergen measures and assessment for asthma/polyps/sinus disease. Repeated oral steroid for routine rhinitis is poor stewardship. |
| Acute asthma exacerbation | Systemic steroid is used in indicated moderate/severe exacerbations to reduce relapse and airway inflammation; inhaled steroid is long-term controller therapy. | Assess severity, oxygenation, peak flow where appropriate and bronchodilator response. Steroids do not replace prompt inhaled bronchodilator, oxygen or escalation. |
| Severe chronic asthma | Use inhaled controller optimisation and phenotype-directed therapy to minimise oral-steroid dependence. | Check diagnosis, inhaler technique, adherence, triggers, smoking exposure and comorbidity before labelling disease “steroid dependent.” |
| Anaphylaxis/angioedema/acute urticaria | May have a later adjunct role in selected inflammatory reactions. | Adrenaline first for anaphylaxis. Do not use steroid as a reason to observe a deteriorating patient without emergency care. |
| Atopic dermatitis / severe skin allergy | Topical steroid is useful when prescribed by potency/site; systemic therapy is reserved for selected severe disease under a plan. | Emollients, infection control, trigger avoidance and correct diagnosis matter; avoid chronic unrestricted potent topical steroid. |
| Allergic conjunctivitis | Usually start with allergen measures and non-steroid options; ophthalmic steroid is specialist-directed for selected severe inflammation. | Exclude keratitis, herpes and glaucoma risk before drops. |
7. The full therapeutic-use map from the lecture—what to say in exams and practice
Acute/chronic adrenal insufficiency, congenital adrenal hyperplasia and stress-dose cover. This is physiological hormone replacement, not “immunosuppression.”
RA, SLE, vasculitis, immune cytopenias, nephrotic/glomerular disease, active hepatitis and selected transplant regimens. Use steroid-sparing therapy where indicated.
Asthma exacerbation, selected severe chronic asthma and specific protocolled lung conditions. Do not generalise to every pneumonia or pulmonary oedema.
Selected TB, lepra reaction, bacterial meningitis, Pneumocystis pneumonia and neurocysticercosis protocols—not routine use in uncontrolled infection.
Ulcerative colitis/Crohn disease, severe inflammatory dermatoses, allergic/inflammatory eye conditions. Local delivery may reduce systemic toxicity.
Cerebral oedema from selected pathology, selected malignancy regimens, thyroid storm, fetal lung maturation and transplant care—always protocol driven.
8. Safe dose scheduling, withdrawal and steroid stewardship
- Write the indication and endpoint: “reduce severe asthma exacerbation relapse risk” is a plan; “give steroid for cough” is not.
- Start with route minimisation: topical/nasal/inhaled/local treatment is often safer when it can adequately reach the disease site.
- Use the minimum effective systemic exposure: short course where evidence supports it, morning administration when suitable, and a stated review/stop date.
- Assess HPA risk: depends on dose, duration, frequency of recent courses, steroid potency/half-life, route and interacting medicines. Long-acting and repeated systemic courses deserve special concern.
- Do not use a universal taper: short courses may stop under their protocol; prolonged/repeated exposure may need an individualised taper that separates disease relapse from adrenal insufficiency. Consult current guidance/specialist team.
- Give a steroid card/emergency advice where indicated: patient and carers must report current/recent steroid use during illness, surgery, emergency care or admission.
9. Adverse effects and monitoring
| System | Adverse effects | Monitoring/prevention |
|---|---|---|
| Fluid/BP/electrolytes | Sodium-water retention, oedema, hypertension, hypokalaemia and heart-failure exacerbation. | Baseline/review BP, weight/oedema and electrolytes where risk/duration warrants; select lower mineralocorticoid activity if appropriate. |
| Glucose/lipids | Hyperglycaemia, steroid diabetes and dyslipidaemia. | Check diabetes history and glucose; create a diabetes-adjustment/monitoring plan before high-dose systemic treatment. |
| Bone/muscle/growth | Osteoporosis, fractures, osteonecrosis, proximal myopathy, growth suppression and delayed puberty. | Fracture-risk assessment, weight-bearing/lifestyle support and condition-specific bone protection; monitor child growth. |
| GI | Dyspepsia, ulcer/bleeding risk especially with NSAIDs, and impaired healing/perforation risk. | Review NSAID/aspirin/anticoagulant use and ulcer history; use gastroprotection when risk indicates, not as a substitute for rational prescribing. |
| Infection | Bacterial, viral, fungal and parasitic infection/reactivation; muted fever/inflammation. | Screen risk before prolonged/intense therapy, assess fever/deterioration urgently and check vaccination implications. |
| Eye/skin | Cataract, glaucoma, blurred vision, skin atrophy, striae, bruising, acne and delayed wound healing. | Ask about vision; eye assessment when indicated; restrict potency/duration on delicate skin. |
| Neuropsychiatric | Insomnia, euphoria, agitation, depression, mania, psychosis and reduced seizure threshold. | Discuss prior psychiatric disease and warn family; urgent review for severe mood/behaviour change. |
| Endocrine | Cushingoid features and HPA-axis suppression/adrenal crisis on abrupt cessation. | Document exposure, taper when indicated and apply stress-dose plan for at-risk patients. |
10. Contraindications are usually risk flags, not a reason to abandon necessary treatment
The lecture lists diabetes, hypertension, peptic ulcer, osteoporosis, TB, viral/fungal infection, herpes simplex keratitis, psychosis, epilepsy, heart failure and renal failure. In modern prescribing these are commonly relative contraindications/precautions. For life- or organ-threatening disease, the right approach is to treat with safeguards: control glucose/BP, exclude or treat infection, add protection/monitoring, seek specialist input and document the benefit–risk decision. Untreated systemic fungal infection and uncontrolled infection require particular caution; never use steroids to hide diagnostic uncertainty.
11. Cases and OSCE revision
Case 1: repeated “allergy injections” for seasonal rhinitis
Ask which product, route and frequency. Repeated systemic/depot steroid for uncomplicated seasonal rhinitis exposes the patient to major harm. Optimise allergen avoidance, intranasal steroid technique and non-sedating antihistamine strategy instead; investigate refractory disease.
Case 2: asthma patient finishes prednisolone then becomes weak, dizzy and vomits during gastroenteritis
Consider dehydration/sepsis but also glucocorticoid-induced adrenal insufficiency if exposure is significant. Ask exact dose/duration/recent courses, assess urgently and use protocolled emergency treatment.
Case 3: diabetic with severe asthma exacerbation
Systemic steroid may still be essential. Explain expected glucose rise, start monitoring and treatment-adjustment plan, and review early rather than withholding indicated therapy without an alternative.
Case 4: red painful photophobic eye treated repeatedly with steroid drops
Stop self-directed escalation and obtain urgent eye assessment. Infection/keratitis/herpes and raised intraocular pressure must be considered.
- OSCE mechanism: glucocorticoids bind intracellular receptors, alter transcription, induce anti-inflammatory proteins and suppress cytokines, phospholipase A2/COX-2 pathways, leukocyte migration and vascular permeability.
- OSCE counselling: state indication, dose/time, route technique, duration, infection and GI/psychiatric/glucose warnings, no sudden stopping after significant exposure, and when to declare steroid use in emergencies.
- Exam trap: antihistamines relieve histamine symptoms; corticosteroids suppress broad inflammation but have delayed effect. Neither replaces adrenaline in anaphylaxis.
- Exam trap: inhaled steroid is controller therapy, not rapid reliever medicine.
Further study and source trail
Supplied source: Pharmacology of Corticosteroids—SlideShare (65 slides). Use the already-published SAIDs/Glucocorticoids foundation lesson alongside current NICE, national and specialty protocols. Doses, equivalence, tapering, asthma action plans, stress dosing, immunisation and pregnancy decisions must follow the latest condition-specific protocol.
